K2 Principal Fund, L.P. Graphite Bio, Inc. Transaction History

K2 Principal Fund, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$1.85 - $3.21 $1.74 Million - $3.02 Million	941,196 Added 3311.27%	969,620 $2.38 Million
Q4 2022 Feb 10, 2023	BUY	$2.82 - $3.59 $80,155 - $102,042	28,424 New	28,424 $94,000
Q2 2022 Aug 12, 2022	BUY	$2.14 - $5.23 $859,584 - $2.1 Million	401,675 New	401,675 $1.11 Million

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of K2 Principal Fund, L.P., based on Form 13F filings with the SEC.

Stay updated on K2 Principal Fund, L.P. with notifications on news.